Advertisement
Advertisement
MTNB
Matinas BioPharma Holdings, Inc.
1.23
USDSponsored
-0.01
-0.81%
Nov 10, 15:51 UTC -5
Closed
After-Market
1.19
-0.04
-3.25%
Matinas BioPharma Holdings, Inc. (MTNB) Earnings
MTNB Earnings Reports
Positive Surprise Ratio
MTNB beat 25 of 34 last estimates.
74%
Next Report
Today
Date of Next Report
Nov 09, 2026
Estimate for Q3 26 (Revenue/ EPS)
--
/--
Implied change from Q2 26 (Revenue/ EPS)
--
/--
Implied change from Q3 25 (Revenue/ EPS)
--
/--
Matinas BioPharma Holdings, Inc. earnings per share and revenue
On Aug 12, 2026, MTNB reported earnings of -- USD per share (EPS) for Q2 26, -- the estimate of -- USD, resulting in a --% surprise. Revenue reached --, compared to an expected --, with a --% difference.
Looking ahead to Q3 26, -- analysts forecast an EPS of -- USD, with revenue projected to reach -- USD, implying an -- of --% EPS, and -- of --% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Definium Therapeutics, Inc. Common Shares
Report Date
Nov 09, 2026 For Q3 26
Estimate
-$0.56
Actual
-$0.46
Surprise
+19.06%
Ocular Therapeutix, Inc.
Report Date
Nov 09, 2026 For Q3 26
Estimate
-$0.36
Actual
-$0.42
Surprise
-13.54%
Harrow, Inc. Common Stock
Report Date
Nov 09, 2026 For Q3 26
Estimate
$0.22
Actual
$0.12
Surprise
-45.92%
SIGA Technologies Inc.
Report Date
Nov 09, 2026 For Q3 26
Estimate
-Actual
-$0.04
Surprise
-
Protara Therapeutics, Inc. Common Stock
Report Date
Nov 06, 2026 For Q3 26
Estimate
-$0.37
Actual
-$0.35
Surprise
+6.17%
Minerva Neurosciences, Inc
Report Date
Nov 06, 2026 For Q3 26
Estimate
-$0.12
Actual
$1.94
Surprise
+1,629.97%
Tonix Pharmaceuticals Holding Corp.
Report Date
Nov 09, 2026 For Q3 26
Estimate
-$2.40
Actual
-$2.89
Surprise
-20.23%
Cumberland Pharmaceuticals Inc
Report Date
Nov 10, 2026 For Q3 26
Estimate
-Actual
-$0.07
Surprise
-
PMV Pharmaceuticals, Inc
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.34
Actual
-$0.28
Surprise
+15.55%
Corbus Pharmaceuticals Holdings, Inc.
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$1.23
Actual
-$1.81
Surprise
-46.07%
FAQ
What were Matinas BioPharma Holdings, Inc.'s earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, Matinas BioPharma Holdings, Inc. reported EPS of --, missing estimates by --, and revenue of --, -- -- expectations.
How did the market react to Matinas BioPharma Holdings, Inc.'s Q2 2026 earnings?
The stock price moved -- --, changed from -- before the earnings release to -- the day after.
When is Matinas BioPharma Holdings, Inc. expected to report next?
The next earning report is scheduled for Nov 09, 2026.
What are the forecasts for Matinas BioPharma Holdings, Inc.'s next earnings report?
Based on --
analysts, Matinas BioPharma Holdings, Inc. is expected to report EPS of -- and revenue of -- for Q3 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.